Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES FIDELIO CAPITAL IN CONNECTION WITH NORDIC CAPITAL’S INVEStMENT IN ANICURA
Mandate

VINGE ADVISES FIDELIO CAPITAL IN CONNECTION WITH NORDIC CAPITAL’S INVEStMENT IN ANICURA

July 01, 2014

Vinge advises Fidelio Capital in connection with Nordic Capital’s investment in AniCura. AniCura is owned by a large number of staff, the Foundation Djursjukhus i Stor-Stockholm and the Swedish investment firm Fidelio Capital. All parties will remain significant co-owners together with Nordic Capital. Through Nordic Capital’s co-ownership, resources will be made available for, among other things, establishing a new veterinary specialist neurological centre at AniCura Albano Animal Hospital in Danderyd, Sweden. Nordic Capital’s investment is subject to approval from the relevant competition authorities.

Partners Jonas Bergström and Johan Winnerblad together with, among others, associates Peter Sundgren, Gustav Jönsson, Amanda Winberg, Johan Mattson, Emelie Klefbeck and project assistant Pernilla Warg advises Fidelio Capital. Partner Marcus Glader advises on competition law.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025